| Autor: |
Kuppili PP; Penn Hospital, Black Country Healthcare NHS Foundation Trust, Wolverhampton WV4 5HN, UK., Menon V; Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Pondicherry, India. drvmenon@gmail.com., Sathyanarayanan G; Department of Psychiatry, Sree Balaji Medical College and Hospital, Chennai, India., Sarkar S; Department of Psychiatry and National Drug Dependence and Treatment Center (NDDTC), All India Institute of Medical Sciences (AIIMS), New Delhi, New Delhi, India., Andrade C; Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of neural transmission (Vienna, Austria : 1996) [J Neural Transm (Vienna)] 2021 Feb; Vol. 128 (2), pp. 253-262. Date of Electronic Publication: 2021 Jan 13. |
| DOI: |
10.1007/s00702-020-02292-x |
| Abstrakt: |
D-Cycloserine is a partial agonist at the glycine site of the N-methyl-D-aspartate (NMDA) receptor. Results have been inconsistent in trials on the efficacy of D-Cycloserine in patients with schizophrenia. We examined the efficacy of D-Cycloserine against negative and cognitive symptoms (primary and co-primary outcomes). Secondary outcomes were efficacy of D-Cycloserine against positive symptoms and the examination of early treatment outcomes. A systematic literature search was carried out using following selection criteria: Population = Patients with Schizophrenia; Intervention = Trials using D-Cycloserine either as monotherapy or adjuvant therapy; Comparison = Placebo or active comparator; Outcome = Change in negative symptoms, cognitive symptoms and positive symptoms; Study design = Randomized controlled trials with parallel design. We used the Cochrane Collaboration tool for risk of bias for study quality appraisal. Effect sizes for trials were calculated separately for negative, positive and cognitive symptom dimensions using the DerSimonian-Laird random effects model. Seven studies (pooled N = 413) provided data for meta-analysis. The pooled Standardized Mean Difference (SMD) for negative, cognitive, and positive symptom change scores were - 0.32 (95% CI, - 0.75 to 0.11), - 0.05 (95% CI, - 0.91 to 0.81), and - 0.08 (95% CI, - 0.37 to 0.20), respectively. No significant improvement was noted with regard to early outcome. I 2 values for heterogeneity were 61%, 67%, and 0% for studies assessing negative, cognitive, and positive symptom ratings, respectively. D-Cycloserine did not exhibit significant efficacy in treating negative, cognitive, or positive symptoms of schizophrenia at either study-defined endpoint (4-36 weeks) or at four weeks (early outcome). |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink